Target identification and validation
Drug discovery and development
Clinical science and correlatives

Target identification and validation

Leverage our technologies to identify and validate potential drug targets:

  • CRISPR/Cas9
  • scRNAseq
  • Flow- and CyTOF-based immune profiling
  • Organotypic spheroids

Our target identification efforts feed directly into our partners’ drug discovery efforts, fueling preclinical development pathways.

Related publications
Screening assay identifies new immunotherapy targets

3D microfluidic device models tumor microenvironment

Drug discovery and development

Our efforts focus on drug evaluation, responder ID, and biomarker discovery to IND submission:

  • In vitro & in vivo pharmacology
  • Patient-derived xenograft (PDX)
  • Syngeneic models of cancer

Our strategic alliances

  • AstraZeneca: Collaboration to address drug-resistant lung cancer
  • Janssen: Collaboration to assess next-generation immunotherapies
  • Daiichi Sankyo: Collaboration to develop novel targeted therapies for lung cancer

Clinical science and correlatives

We accelerate clinical research:

  • Liquid biopsy to augment precision medicine
  • Immune profiling to characterize patients treated with checkpoint blockade

Related publications
Defining inflammatory microenvironment in head & neck cancer

“Hot” and “cold” immunophenotypes identified in lung cancer

Plasma NGS panel developed to identify targetable NSCLC mutations